































Annals of Hepatology 18 (2019) 620–626
Contents lists available at ScienceDirect
Annals  of  Hepatology
jou rn al h om epa ge : www.elsev ier .es /annalsofhepato logy
riginal  article
dvantages  of  adipose  tissue  stem  cells  over  CD34+ mobilization  to
ecrease  hepatic  fibrosis  in  Wistar  rats
arcela  M.  De  Luna-Saldivara,b,  Iván  A.  Marino-Martinezc, Moisés  A.  Franco-Molinaa,
ydia G.  Rivera-Moralesa,  Gabriela  Alarcón-Galvánd, Paula  Cordero-Pérezb,
ugusto  Rojas-Martíneze,  Cristina  Rodríguez-Padillaa,  Linda  E.  Muñoz-Espinosab,∗
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a  b  s  t  r  a  c  t
Introduction  and Objectives:  Chronic  liver  inflammation  may  lead  to hepatic  cirrhosis,  limiting  its  regen-
erative  capacity.  The  clinical  standard  of  care  is  transplantation,  although  stem  cell therapy  may  be  an
alternative  option.  The  study  aim was  to induce  endogenous  hematopoietic  stem  cells  (HSCs)  with  gran-
ulocyte  colony  stimulating  factor  (G-CSF)  and/or  intravenous  administration  of adipose  tissue-derived
mesenchymal  stem  cells  (MSCs)  to decrease  hepatic  fibrosis  in  an  experimental  model.
Material  and  methods:  A  liver fibrosis  model  was  developed  with  female  Wistar  rats  via  multiple  intraperi-
toneal  doses  of  carbon  tetrachloride.  Three  rats  were  selected  to confirm  cirrhosis,  and  the  rest  were  set
into  experimental  groups  to evaluate  single  and  combined  therapies  of G-CSF-stimulated  HSC mobiliza-
tion  and  intravenous  MSC  administration.
Results:  Treatment  with  MSCs  and  G-CSF  significantly  improved  alanine  amino  transferase  levels,  while
treatment  with  G-CSF,  MSCs,  and  G-CSF  + MSCs  decreased  aspartate  amino  transferase  levels.  Hepatocyte
growth  factor  (HGF)  and interleukin  10 levels  increased  with  MSC  treatment.  Transforming  growth  factor
 levels  were  lower with MSC  treatment.  Interleukin  1 and  tumor  necrosis  factor  alpha  levels  decreased
in  all  treated  groups.  Histopathology  showed  that  MSCs  and  G-CSF  reduced  liver  fibrosis  from  F4  to  F2.
Conclusions:  MSC  treatment  improves  liver  function,  decreases  hepatic  fibrosis,  and  plays  an  anti-
inflammatory  role;  it promotes  HGF  levels  and  increased  proliferating  cell  nuclear  antigen  when  followed
by  MSC  treatment  mobilization  using  G-CSF.  When  these  therapies  were  combined,  however,  fibrosis
improvement  was  less  evident.
© 2019  Fundación  Clı́nica  Médica  Sur,  A.C. Published  by Elsevier  España,  S.L.U.  This  is an  open  access
he CCarticle  under  t
. Introduction
Chronic liver inflammation may  be caused by viruses, alcohol,
utoimmunity, and fatty liver disease, leading to cirrhosis [1–3].
epatic failure occurs when hepatic progenitor cell niches burn out,imiting the organ’s regenerative capacity [4]. The clinical standard
f care is liver transplantation, though the low donor availability
nd high costs make this option less practical. Another treatment
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option is stem cell therapy [5,6] based on two  strategies: (1) mobi-
lization of endogenous hematopoietic stem cells (HSCs) induced
by administration of granulocyte colony stimulating factor (G-CSF)
or (2) inoculation of exogenous HSCs or mesenchymal stem cells
(MSCs) [7].
MSCs are multipotent, non-hematopoietic stromal cells. They
probably reside in a perivascular niche in vivo and can be iso-
lated from various organs and tissues, including adipose tissue (AT)
[8]. MSCs can contribute to the direct production of new hepato-
cytes, can promote tissue repair by secreting trophic molecules,
are immunomodulatory, have antifibrotic properties, and inhibit
activation of hepatic stellate cells [9]. In bone marrow (BM),
MSCs comprise around 0.001–0.08% of cells and mobilize to the
peripheral circulation following experimental injury [8,10]. AT is
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lso a good source of MSCs, with a high proliferative potential
11,12]; one gram of AT has 500 times more MSCs than BM and
 better proliferative capacity than BM-derived MSCs [13,14]. Clin-
cal studies using AT-derived MSCs showed improved histology
nd liver function in human and animal subjects [15–19]. Further-
ore, the easy access to subcutaneous AT, the ability to repeatedly
ample this tissue, and the uncomplicated enzyme-based isolation
rocedures make AT the most attractive source of MSCs [20].
Another strategy for stem cell therapy is to stimulate the
obilization of HSCs from BM into the blood stream through
dministration of G-CSF [21]. Mobilization of endogenous HSCs
sing G-CSF is also a promising treatment for acute and chronic
iver damage in animal models [16,22–24]. BM-resident HSCs can
e mobilized into the peripheral blood at a low rate under spe-
ific stimuli, such as tissue injury [16,25,26], or at high rates
ith pharmacologic priming with cytostatic drugs, chemokines, or
ematopoietic cytokines [27,28]. G-CSF is a hematopoietic growth
actor that mediates HSC mobilization to peripheral blood and rep-
esents the most widely used mobilizing agent [29]. Several reports
ave suggested that G-CSF mobilized HSCs contribute to liver repair
n acute and chronic liver injury models [30,31]. The synergistic
ffect of HSC and MSC  therapies have been observed in heart fail-
re patients and in neovascularization processes in bioengineered
one [32,33].
Thus, the study aim was to use endogenous HSCs via G-CSF
nd/or intravenous administration of AT-derived MSCs to improve
iver function and decrease hepatic fibrosis in an experimental
odel.
. Material and methods
.1. Isolation and characterization of MSCs derived from adipose
issue
We  obtained MSCs from inguinal fat AT of male rats (2
onths of age, 225 ± 25 g body weight). The fat was collected in
hosphate buffered saline (BioWest, France) containing 2% antibi-
tic/antimycotic (BioWest) and incubated for 1 h at 4 ◦C. AT was
omogenized and subsequently digested with collagenase type I
0.1%) (Gibco, USA) for 30 min  at 37 ◦C under constant stirring. After
wo phases were visualized, the lower phase was collected and
entrifuged at 1500 rpm for 3 min. The supernatant was removed,
nd the pellet was washed three times with sterile phosphate
uffered saline at 1500 rpm for 3 min. The cell pellet was  sus-
ended in Dulbecco’s Modified Eagle’s Medium (BioWest), 10% fetal
ovine serum (BioWest) and 1% antibiotic/antimycotic (BioWest).
he medium was changed every 3 d until the monolayer of adherent
ells reached 80% confluence. Cell passaging was  performed using
.25% trypsin-ethylenediaminetetraacetic acid solution (BioWest)
ntil the third passage, after which the cells were used for trans-
lantation according to procedures described by Tobergte et al.
34].
Expression of the markers CD105, CD90, CD45, CD34, and
-actin as an internal control was determined by quantitative real-
ime polymerase chain reaction using the primers: CD105 (5′-TGG
CT TTT CGA ACG AGA ATG-3′/5′-AGC CGG AGG ACA ATG CTT
TG G-3′); CD90 (5′-TTT ATC AAG GTC CTT ACT CTA GCC-3′/5′-
AG TCA CAG AGA AAT GAA GTC C-3′); CD45 (5′TCC ACG GGT
TT CAG CAA GTT TC-3′/5′-CCA GAT CAT CTT CCA GAA GTC ATC-
′); CD34 (5′-AAG ATC TTG GGA GCC ACC AGA G-3′/5′-TAG CCC
GG CCT CCA CCA TTC-3′); and -actin (5′-GTC ACC TGG GAC
AT ATG G-3′/5′-AAG TCT AGG GCA ACA TAG CAC AG-3′). Ribonu-
leic acid extraction of MSCs from AT during the third passage
as with Trizol
®
(Invitrogen, USA), performed according to the
anufacturer’s instructions, and complementary deoxyribonucleicf Hepatology 18 (2019) 620–626 621
acid was  synthesized using SuperScriptTM III First-Strand Synthesis
SuperMix (Invitrogen, USA), SYBR
®
GreenERTM quantitative real-
time polymerase chain reaction SuperMix (Invitrogen, USA) and
analyzed with the method.
2.2. Animal model of liver fibrosis and stem cell therapy
administration
We used female Wistar rats with a body weight of 225 ± 25 g
raised with free access to water and food and on 12-h light/dark
cycles. All studies were performed according to the Mexican Official
Regulation (NOM-062-ZOO-1999) regarding the technical speci-
fications for the production and care of laboratory animals. The
research protocol was  approved by the Institutional Animal Ethics
Committee at the School of Medicine and the “Dr. José Eleuterio
González” University Hospital, Universidad Autónoma de Nuevo
Leon, (reference number: HI14-001).
To induce the liver fibrosis model, 15 female Wistar rats
were injected intraperitoneally with carbon tetrachloride (CCl4)
(Sigma–Aldrich, USA) at doses that increased weekly at 500, 570,
650, 850, and 1000 mg  3× weekly over 8 weeks (wks), according
to the modified protocol described by Muriel et al. [35]. At the end
of the 8 wks, CCl4 was  stopped, and we  randomly selected three
rats to confirm histopathologically that they had developed cirrho-
sis (see below). Each group included 3 Wistar rats. The negative
control group received mineral oil intraperitoneally, and the CCl4
group was the positive control for the experimental cirrhosis. The
next three groups received the experimental treatment at week
(wk) 9. In all groups, CCl4 was  stopped at wk 8. Group CCl4 + G-
CSF received 3 doses of G-CSF 300 g/kg/3d at wk  9 (days 1, 2,
and 3). Group CCl4 + MSC  received 1 dose of 3 × 106 MSC  at wk 9
(day 1), and group CCl4 + G-CSF + MSC  received 3 doses of G-CSF
300 g/kg/3d at wk 9 (days 1, 2, and 3) and 1 dose of 3 × 106 MSC
at wk  10 (day 1).
2.3. Determination of CD34+ surface marker
We evaluated circulating CD34+ before and after G-CSF treat-
ment in all groups. Erythrocytes were lysed using BD FACSTM lysing
solution (BD Biosciences, San José, CA) according to the manu-
facturer’s instructions. The anti-CD34 antibody (Abcam, USA) was
added in 1:50 proportion and incubated for 30 min  at room tem-
perature. The stained cells were analyzed with Accuri C6 flow
cytometer and CFlow plus software (BD Biosciences).
2.4. AST, ALT, and growth factor and cytokine analysis
Blood samples were drawn from all groups at 8 and 16
wks to perform aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) using standard commercial biochemical
assay kits (Ilab Plus 300, Instrumentation Laboratory, Italy). The
hepatocyte growth factor (HGF) (R&D Systems, USA) and trans-
forming growth factor beta (TGF-)  (Abcam PLC, Cambridge, UK)
were determined with enzyme linked immunosorbent assay using
the multi-detection microplate reader (Biotek Instruments, USA).
Interleukin 1beta (IL-1), interleukin 6 interleukin 10 (IL-10), and
tumor necrosis factor alpha (TNF-)  (Merck, Darmstadt, Germany)
were measured by a Luminex analyzer (Merck). All analyses were
run according to the manufacturer’s instructions.
2.5. Histopathological analysisAt 16 wks, the rats were sacrificed by cervical dislocation and the
livers removed by dissection, fixed in 10% formalin, and embedded
in paraffin wax. Tissues were stained with hematoxylin and eosin
Masson’s trichrome, and sirius red. Histopathological analysis was







IRS score (A × B)
0 = no positive cells 0 = no color reaction 0–1 = negative
1  = <10% of positive cells 1 = mild reaction 2–3 = mild








































and 16 wks  compared with the control group. In the treated3  = 51–80% positive cells 3 = intense reaction 9–12 = strongly positive
4  = >80% positive cells Final IRS score (A × B) = 0–12
erformed using the Olympus BH-2 optical microscope (Olympus
ptical, USA). The degree of hepatic fibrosis was based on a histo-
ogical grading scale using the METAVIR score [36]. The fibrosis was
raded on a 5-point scale from F0 to F4.
Image analysis was performed to determine fibrosis score
n micrographs of sirius red stained sections. Thirty fields per
lide area were analyzed using ImageJ program version 2.0.0-rc-
3/1.50E.
.6. Immunohistochemical study of proliferating cell nuclear
ntigen expression
Paraffin-embedded samples at 8 and 16 wks were stained for
mmunohistochemistry with primary antibody proliferating cell
uclear antigen expression (PCNA) (1:4000) (Abcam, Cambridge,
K) with the mouse- and rabbit-specific HRP/DAB (ABC) detec-
ion immunohistochemistry kit (Abcam, Cambridge, UK) according
o the manufacturer’s instructions. The immunoreactive score was
alculated as the product of the positive cell proportion score (0–4)
ultiplied by the staining intensity score (0–3) (Table 1) [37].
.7. Statistical analysis
The results are presented as mean ± standard deviation (SD).
etween-group differences were assessed for statistical signifi-
ance with Student’s t-test and p < 0.05 was considered statistically
ignificant. Statistical analyses were performed using SPSS 19.0
omputer software package (SPSS Inc, Chicago, IL).
. Results
.1. Specific markers of MSCs derived from AT
From the third passage cell culture, MSCs were characterized
rom a culture of adherent cells with fusiform appearance. Rela-
ive gene expression of specific markers for MSCs and HSCs were
easured by quantitative real-time polymerase chain reaction in
omplementary deoxyribonucleic acid. Relative to expression of -
ctin messenger ribonucleic acid, specific markers of MSC  CD90+
nd CD105+ were 60.5 ± 0.1% and 24.8 ± 0.1%, respectively. Low
essenger ribonucleic acid expression of hematopoietic markers
D34 4 ± 1.5% and CD45 10.4 ± 0.4% was detected.
.2. Expression CD34+ in peripheral blood
The population of CD34+ was analyzed before and 24 h after
reatment with G-CSF. Treatment induced a significant mobiliza-
ion of hematopoietic CD34+ cells in: CCl4 + G-CSF (0.20 ± 0.17%
efore vs. 1.50 ± 0.50% after treatment, p < 0.01) and CCl4 + G-
SF + MSC  (0.57 ± 0.25%, before vs. 1.70 ± 0.36% after treatment, < 0.05). We  did not find differences in either the control
0.20 ± 0.10% before vs. 0.21 ± 0.05% after saline, p = NS) or CCl4
0.13 ± 0.06%, before vs. 0.016 ± 0.05%, after saline, p = NS).f Hepatology 18 (2019) 620–626
3.3. AST and ALT
AST and ALT were significantly decreased in the groups treated
with CCl4+G-CSF and CCl4+MSC compared with the CCl4 group at
16 wks  (p < 0.001). In addition, AST decreased in CCl4+G-CSF+MSC
(p < 0.05) compared with the CCl4 group (Fig. 1A, B).
3.4. Growth factor levels
HGF levels of the positive control (CCl4) remained similar at
8 and 16 wks (p = NS) (Fig. 1C), whereas they decreased signifi-
cantly at 16 wks in CCl4+G-CSF (p < 0.01). Levels of HGF significantly
increased in CCl4+MSC at 16 wks vs. CCl4 group (p < 0.05) (Fig. 1C).
There was  no significant difference between TGF- at 8 vs. 16 wks
in the control group. However, a significant decrease in TGF- levels
was observed between 8 and 16 wks in the CCl4 group (p < 0.01). At
16 wks  a significant decrease in TGF- levels was seen in CCl4+MSC
(p < 0.01) and CCl4+G-CSF+MSC (p < 0.05) (Fig. 1D).
3.5. Production of serum inflammatory cytokines
A natural recovery in IL-1 and interleukin 6 seemed to occur at
16 wks (p < 0.001) in the CCl4 group (Figs. 1 E,F). However, the three
treatment groups had significant decreases in IL-1 (p < 0.001)
(Fig. 1E), in contrast to interleukin 6 levels that were not altered
by treatment groups (Fig. 1F). IL-10 was increased at 16 wks in all
treatment groups: CCl4+G-CSF (p < 0.05), CCl4+MSC, and CCl4+G-
CSF+MSC vs. CCl4 (both p < 0.001) (Fig. 1G). TNF- levels were
decreased in all treatment groups: CCl4+G-CSF (p<0.05), CCl4+MSC,
and CCl4+G-CSF+MSC (both p<0.001) (Fig. 1H).
3.6. Histopathological examination
The CCl4 group showed hepatocellular degeneration, with pres-
ence of medium and small nodules with well-formed fibrous bands
at 8 wks (METAVIR F4) (Fig. 2D–F). However, at 16 wks, bridging
fibrosis with the presence of medium nodules with thin fibrous
bands was  observed (METAVIR F3) (Fig. 2G–I). At 16 wks, the
CCl4+G-CSF and CCl4+MSC groups showed presence of septa and
thin bridging (METAVIR F2) vs. CCl4 at 8 wks (Fig. 2J, K, L, M,  N, O).
At 16 wks, the CCl4+G-CSF+MSC group showed presence of septa,
thin bridging, small and medium nodules, and decreased fibrosis
to F3 vs. CCl4 at 8 wks, but no difference was  found compared with
the CCl4 group at 16 wks  (METAVIR F3) (Fig. 2P, Q, R).
3.7. Quantification of collagen in liver tissue
In the CCl4 group, the percentage of collagen was  significantly
increased by 20.81 ± 0.31% at 8 wks compared with the control
group, 0.67 ± 0.01% (p < 0.0001). In the former, there was a spon-
taneous reduction of collagen quantification to 7.81 ± 0.68% at 16
wks (p < 0.001). However, in the treated groups there was further
collagen reduction at 16 wks: CCl4+G-CSF, 2.02 ± 0.45%; CCl4+MSC,
2.32 ± 0.22%; CCl4+G-CSF+MSC, 3.57 ± 0.29% (p < 0.001) (Fig. 3A).
3.8. Proliferating cell nuclear antigen expression
In the CCl4 group, PCNA expression decreased (p < 0.05) at 8groups, PCNA expression was  significantly increased in CCl4+G-CSF
(p < 0.001), CCl4+MSC (p < 0.001), and CCl4+G-CSF+MSC (p < 0.05)
compared with CCl4 group at 16 wks (Fig. 3B).
M.M. De Luna-Saldivar et al. / Annals of Hepatology 18 (2019) 620–626 623



































important roles in liver injury. Studies of kidney and lung injury
and fulminant hepatic failure models have demonstrated thatnzymes: (A) Alanino aminotransferase (ALT); (B) Aspartato aminotransferase (AST
 (TGF-). Inflammatory cytokines: (E) Interleukin 1 (IL-1); (F) Interleukin 6 (I
p  < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
. Discussion
Isolated treatment with AT-derived MSCs showed better
mprovement in liver function compared with G-CSF-mobilized
SC. MSC  had the best results when comparing the three thera-
ies against the positive control, on HGF, TGF-, and IL-10 (p < 0.05,
 < 0.01 and p < 0.01, respectively) levels. However, differences
ere not observed in either biopsied tissue or quantification of
ollagen. HGF and TGF- levels reflect better conditions for the
egenerative process; this may  be seen before the histological
hanges. Less improvement was observed when these thera-
ies were combined. In all treatment groups, IL-1 and TNF-
ecreased, likely reflecting an anti-inflammatory effect. Likewise,
n elevation in IL-10 was observed, which may reflect down-
egulation of inflammatory cytokines. In addition, treatment of
xperimental cirrhosis with MSCs stimulated the highest levels
f HGF and inhibited TGF-, which may  reflect a better homing
apacity of MSC  than of HSC.
MSCs derived from AT were characterized by adherence to plas-
ic and expression profiles of specific markers according to Lofty
t al. [14], who showed high expression of CD90 and CD105 and
ow expression of CD34 and CD45. We  found that G-CSF induces
obilization of HSC expressing CD34+ surface markers. Accord-
ngly, Mark et al. [23] observed an increase in CD34+ population
n an experimental, acute model of CCl4 using G-CSF.
Increased hepatic enzymes (ALT and AST), TGF- [38,39], IL-1,
nd TNF- pro-inflammatory cytokines are parameters associated
ith liver damage, fibrosis, and active inflammation [40,41]. Sim-
larly, in a chronic injury model of CCl4 treated with MSCs [42],
here was an improvement in liver function and diminished ALT and
ST. In addition, treatment with G-CSF [16] ameliorated liver dam-
ge and decreased ALT [16,39,42]. ALT is a more specific enzyme
f liver damage than AST. However, in our model, improvement
as reflected by a decrease in AST in all treatment groups, whereas
LT improvement was seen in CCl4+G-CSF and CCl4+MSC but notwth factors: (C) Hepatocyte growth factor (HGF); (D) Transforming growth factor
G) Interleukin 10 (IL-10); (H) Tumor necrosis factor  (TNF-). Mean ± SD (n = 3).
in CCl4+G-CSF+MSC. With these experiments, it is impossible to
determine why  there is a different response between ALT and AST.
A decrease in TGF- may  be associated with diminished fibrosis
[43]. In our model, both CCl4+MSC (p < 0.01) and CCl4+G-CSF+MSC
(p < 0.05) groups had a significant impact on decreasing TGF-.
Changes in HGF and TGF- serum levels may  not be reflected in liver
histology in our model, possibly because a short period of observa-
tion was  used to define whether these growth factors predict the
evolution of fibrosis. In our model, the increase in HGF and decrease
in TGF- in the three groups suggests an adequate response to
therapy, with elevated HGF indicating repair and decreased TGF-
indicating decreased fibrosis.
In vitro studies have shown that MSCs in culture can produce
HGF and inhibit hepatic stellate cells [22] and in vivo studies of
experimental fibrosis have shown that MSCs increase levels of
circulating HGF [22,42], stimulating regeneration and accelerat-
ing hepatocyte proliferation [31,39]. In the current study, MSCs
stimulated the highest increase of HGF, possibly reflecting dam-
age repair. Further, PCNA increased in MSCs and G-CSF (p < 0.001)
and G-CSF+MSC (p < 0.05) groups. Li et al. [9] addressed the thera-
peutic effects of MSC  and HSC in an experimental cirrhosis model,
and placed emphasis on MSC  having a greater homing capacity
for the injured liver and greater capacity to promote hepatocyte
proliferation.
In another liver fibrosis model treated with MSCs [43], IL-1
and TNF- decreased, consistent with our findings. It has also been
shown previously that TNF- decreases with G-CSF treatment [16].
In addition, in this study, combined therapy showed a significant
decrease in TNF- (p < 0.0001), possibly indicating a strong anti-
inflammatory effect.
MSCs and HSCs have immunomodulatory properties and playIL-10 plays an anti-inflammatory role [44–46]. A possible anti-
inflammatory role of IL-10 was observed in all treatment groups.
624 M.M. De Luna-Saldivar et al. / Annals of Hepatology 18 (2019) 620–626
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ig. 2. Histopathological analysis of liver tissue of the groups evaluated before trea
richrome (MT); right, sirius red (SR); A (H&E), B (MT), C (SR): Control; D (H&E), E (
Cl4+G-CSF 16 weeks; M (H&E), N (MT), O (SR): CCl4+MSC 16 weeks; P (H&E), Q (M
revious studies with a similar model with MSC  treatment reported
n increase in IL-10 [42,43]. Discrepancies across studies relate to
he mechanisms that mediate immunosuppression, which may  be
ue to different experimental conditions or the origin of the MSCs
47]. Although these mechanisms are not wholly understood, MSCs
re able to inhibit the proliferation of T cells, to inhibit the produc-
ion of interferon gamma  and TNF-, and to induce an increase
n interleukin 4 and IL-10 levels. Cumulatively, these findings indi-
ate a pro-inflammatory immune response in an anti-inflammatory
tate, which is favored by stimulation of the Treg lymphocytes and
lterations in dendritic cell activities [47].
The MSCs are also able to interfere in the differentiation, mat-
ration, and function of dendritic cells, causing a blockade in the
mmature state and altering secretion of cytokines. For example,
SCs can reduce production of proinflammatory cytokines inter-
eukin 12, interferon gamma, and TNF- and increase production
f anti-inflammatory cytokines such as IL-10 [48].
Treatment with MSCs and G-CSF improves liver fibrosis in CCl4
hronic liver injury models [24,50,51]. Similarly, our results showed
 decrease from F4 to F2 in the METAVIR score and diminished
ollagen fibers, especially when treatments were used separately.
everal mechanisms by which these cells might contribute to
ecreased fibrosis have been proposed, including their differenti-
tion into hepatocytes, their fusion with endogenous hepatocytes,
nd a proliferative paracrine effect on hepatocytes [49].t and after 8 and 16 weeks. Left side, hematoxylin & eosin (H&E); center, Masson’s
 (SR): CCl4 8 weeks; G (H&E), H (MT), I (SR): CCl4 16 weeks; J (H&E), K (MT), L (SR):
SR): CCl4+G-CSF+MSC 16 weeks. Amplification (100×).
HSCs participate in hepatic proliferation and repair after injury
[52–56] although the true contributions of BM stem cells to liver
regeneration has been questioned [31,57,58]. Evidence suggests
that rather than transdifferentiation of HSCs to tissue-specific stem
cells or fusion of donor with host cells, replenishment of damaged
tissues occurs through activation of endogenous progenitors and
repair mechanisms mediated by paracrine secretion of soluble fac-
tors by BM cells [59–61]. G-CSF, by means of forced circulation of
large numbers of HSCs, has been extensively investigated for its
hepatic regenerative effect, both in animal models of liver injury
[30,31,62] and clinical trials [63–65].
In our model, the CCl4 group at 8 wks, compared to the CCl4
group at 16 wks, decreased from F4 to F3. Muriel et al. [35] reported
that the degree of fibrosis increased linearly with duration of CCl4
treatment, but spontaneous regression of fibrosis was similar after
2 or 3 months of chronic intoxication, and discontinuation of the
toxin for two months produced a significant but relatively small
reduction in fibrosis.
In this study, the G-CSF+MSC combination showed less improve-
ment compared to separate use of MSCs and G-CSF treatments. A
synergistic or additive effect was  not observed. In previous studies,
a synergistic effect was  demonstrated when MSCs in combination
with G-CSF were successfully used as a treatment for ulcerative
colitis in rats, suggesting that G-CSF increased recruitment of MSCs
[49]. However, in a study by Li et al. [9], the synergistic effect of
M.M. De Luna-Saldivar et al. / Annals of Hepatology 18 (2019) 620–626 625




































ig. 3. Quantification of collagen in liver tissue and immunohistochemical analys
ercentage stained with sirius red. (B) Immunohistochemistry proliferating cell nu
ignificant differences in both analysis. *p < 0.05, **p  < 0.001.
SCs and HSCs (derived from non-autologous BM)  treatment was
ot observed in liver injury; this group obtained better results with
SCs than with HSC in mice. We  used G-CSF to promote HSC CD34+
utologous mobilization as a possible increase in recruitment of AT
SCs. We  did not observe the additive or synergistic effect between
SCs and G-CSF therapies in this chronic CCl4 model. However,
hese experiments were not designed to explain some mechanisms.
In conclusion, our results showed that MSC  treatment improved
iver function, diminished inflammatory activity, decreased hepatic
brosis, played an anti-inflammatory role, promoted HGF pro-
uction, and increased PCNA following treatment with HSC
obilization using G-CSF. However, combined therapies showed
ess improvement in liver fibrosis. It will be necessary to carry
ut experiments using higher doses and administration frequen-
ies. Larger experimental groups will also allow assessment of the







-CSF granulocyte colony stimulating factor
GF hepatocyte growth factor
SCs hematopoietic stem cells
L-1 interleukin 1beta
L-10 interleukin 10
SCs mesenchymal stem cells
CNA proliferating cell nuclear antigen
GF- transforming growth factor beta




the groups evaluated after treatment at 16 weeks. (A) Quantification of collagen
antigen (PCNA) in liver tissue: evaluation of staining intensities. Mean ± SD (n = 3).
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